Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of subcutaneous hdmASIT+TM in house dust mite-induced allergic rhinoconjunctivitis
2016-000557-13Phase 2Completed
- Sponsor
- ASIT Biotech
- Start
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of hdm-ASIT+ in allergic rhinoconjunctivitis (ARC), sponsored by ASIT Biotech. Primary endpoint: Primary safety and tolerability endpoint. Started Apr 2016; status: completed.
02
Drugs
hdm-ASIT+
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2016-000557-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000557-13.